The data were generated from three blinded studies of preclinical models of colon carcinoma randomized into three experimental groups. The models were treated with suboptimal doses of motesanib diphosphate (37.5–75 milligrams per kg QD, PO), bevacizumab (2.8 micrograms twice per week), AMG 386 (2.8-14 micrograms twice per week) or combinations thereof.
Roger Perlmutter, Amgen’s executive vice president of R&D, said: “What’s encouraging about these early results is that they indicate that blocking more than one angiogenesis pathway may offer enhanced potential to inhibit tumor growth. We look forward to investigating this finding further.”